Skip to main content
David Siegel, MD, Oncology, Hackensack, NJ, Hackensack Meridian Health Hackensack University Medical Center

DavidSSiegelMDPhD

Oncology • Hackensack, NJ

Hematologic Oncology

Chief, Myeloma Division John Theurer Cancer Center, Hackensack University Medical Center. Founding Director, Institute for Multiple Myeloma. Center for Discovery and Innovation

Request Appointment

Overview of Dr. Siegel

Dr. David Siegel is an oncologist in Hackensack, NJ and is affiliated with multiple hospitals in the area, including Hackensack Meridian Health Hackensack University Medical Center and MedStar Georgetown University Hospital. He received his medical degree from NYU School of Medicine and has been in practice 31 years. He specializes in hematologic oncology and is experienced in multiple myeloma, bone marrow transplant, AL amyloidosis and Waldenstroms Macroglobulinemia.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 1987 - 1989
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineInternship, Internal Medicine, 1986 - 1987
  • New York University School of Medicine
    New York University School of MedicineClass of 1986
  • New York University
    New York UniversityPhD, 1985
  • New York University
    New York UniversityMSc, 1984
  • American Association of Immunologists
    American Association of ImmunologistsCertificate, Advanced Immunology Course, 1984
  • Cook College, Rutgers University
    Cook College, Rutgers UniversityB.S., With Honors, 1979

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 1998 - 2025
  • DC State Medical License
    DC State Medical License 2012 - 2024
  • NY State Medical License
    NY State Medical License 1987 - 2024
  • AR State Medical License
    AR State Medical License 1995 - 1999
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Fellow (FACP) American College of Physicians, 2002
  • Young Investigator Award ASCO, 1991
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVOR  
    Ruben Niesvizky, David Siegel, Ralph Boccia, Blood
  • Updated survival analyses after prolonged follow-up of the phase 2, multicenter CReST study of bortezomib in relapsed or refractory multiple myeloma  
    Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG,Niesvizky R, Alexanian R, Limentani SA, Alsina M, esseltine DL, Anderson KC, Br J Haematol, 1/1/2014
  • Phase I Trial of Anti-CS1 Monoclonal Antibody elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma  
    Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar De, Singhal AK, Anderson KC, J Clin Oncol, 1/30/2012
  • Join now to see all

Books/Book Chapters

  • Advances in Internal Medicine 
    Chapter: Advances in the treatment of multiple myeloma. 
    Barlogie B, Jagannath S, Tricot G, Desikan KR, Fassas A and Siegel DMosby-Year Book1998
  • C-Myc in B-Cell Neoplasia. 14th Workshop on Mechanisms in B-Cell Neoplasia 
    Chapter: Myc/Max family of transcription factors and bcl-2 are involved in drug-induced apoptosis of myeloma cells. 
    Siegel DS, Terry JA, Koury J, Barlogie B, epstein J and Feinman REditors: Potter M and Melchers F.Springer-Verlag1997
  • The Interferon System 
    Chapter: Interferon-gamma induction in peripheral blood leukocytes by interleukin-2: Role of monocytes, interleukin-1 and interferon-gamma. 
    Vilcek J, Henriksen-DeStefano D, Siegel D and Le JEditors: Dianziani F and Rossi GB.Raven Press1984

Lectures

  • CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia _ Clinical Updates and Innovations 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma
    First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple MyelomaNovember 20th, 2019
  • FDA Approves Kyprolis (Carfilzomib) Once-Weekly Kd70 Regimen for Relapsed or Refractory Multiple Myeloma
    FDA Approves Kyprolis (Carfilzomib) Once-Weekly Kd70 Regimen for Relapsed or Refractory Multiple MyelomaNovember 29th, 2011
  • Despite Recent Improvement, Childhood Cancer Diagnoses Are More Common Than 15 Years Ago, Study Finds
    Despite Recent Improvement, Childhood Cancer Diagnoses Are More Common Than 15 Years Ago, Study FindsJuly 12th, 2023
  • Join now to see all

Committees

  • Working Group Member, International Waldenstrom's Macroglobulenemia Working Group 2011 - 2016
  • Steering Committee, MMRF 2005 - 2016
  • group Member, International Myeloma Working Group 2005 - 2016

Research History

  • Chief, Myeloma Division12 current clinical trials2002 - 2016

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    AmeriHealth Direct POS
    Amerihealth HMO
    AmeriHealth PPO
    BCBS Blue Card PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    First Health PPO
    GHI PPO
    Great West PPO
    Healthfirst New York
    HIP of New York - Select PPO
    Horizon BCBS Direct Access
    Horizon BCBS HMO
    Horizon BCBS POS
    Horizon BCBS PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. David Siegel, Dr. David Siegel, MD, Dr. D Siegel, Dr. David S Siegel